Personalized chemotherapy

The basis of most cancer treatment regimens remains chemotherapeutic drugs, which are not selected based on biomarkers or molecular profiling (unlike targeted or immunotherapy). Cancer is an extremely heterogeneous genetic disease, so each patient responds differently to the same chemotherapy regimen. The effectiveness or ineffectiveness of treatment is determined retrospectively. Currently, there are no opportunities to prospectively identify patients whose cancer is already resistant or has acquired resistance to chemotherapeutic drugs. This creates a risk of treatment failure and disease progression, further increasing the burden of cumulative toxicity from successive ineffective treatments.
This is why oncologists need a reliable test to identify cases of innate or emerging chemoresistance in tumor cells, allowing for timely detection of treatment failures. This approach will enable more effective treatment management decisions, reducing the risks associated with ineffective treatment and the associated toxicity.

Chemo-scale studies the direct effect of drugs on circulating tumor cells/clusters and helps create an individualized treatment plan based on the detected sensitivity or resistance.
Chemo-scale minimizes the risks of unsuccessful therapy for the patient: saves money, reduces the number of "trials and errors", improves the "attack on cancer", but not on the patient.

Determining the individual sensitivity of circulating tumor cells/clusters shows a high concordance rate (93.7%) with sensitivity assessments from tumor cells derived from fresh biopsy samples, as well as with clinical outcomes

The high clinical benefit of Chemo-scale in selecting effective chemotherapeutic drugs has been convincingly demonstrated in studies involving more than 5,000 patients.